Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

IgG/IgM, Polyclonal, Secondary Antibody, BD

Supplier:  BD Biosciences 555988

Catalog No. BDB555988


Get 2 Extra BD Antibodies When You Buy 4
View Available Promotions
Only null left
Add to Cart

Description

Description

Monoclonal antibody BB9 recognizes a cell-surface glycoprotein of approximately 160kDa, expressed on primitive hematopoietic progenitor cells (HPC). This antibody was generated using human bone marrow-derived stromal cells as immunogen. BB9 reacts with stromal cells, a minor subset of human bone marrow cells; it does not react with peripheral blood leukocytes. Reacts with a subset of CD34+, CD90+ demonstrating low or absent expression of CD38, low retention of Rhodamine 123 and Ki-67-. CD34+BB9+ cells are able to sustain hematopoiesis in pre-CFU culture stimulated with IL-3, IL-6, G-CSF and SCF. BB9 also reacts with a subset of CD34+ cells from mobilized peripheral blood.

Host Species: Mouse
Isotype: IgG1, κ
Species Reactivity: Goat
Immunogen: Human bone marrow-derived stromal cells

Flow Cytometry

TRUSTED_SUSTAINABILITY
Specifications

Specifications

IgG/IgM
POLYCLONAL
Goat
RUO
Secondary
Ig
Monoclonal
FITC
0.1 mg
Immunology
Mouse
Product Suggestions

Product Suggestions

Videos
Safety and Handling

Safety and Handling

WARNING: Reproductive Harm - www.P65Warnings.ca.gov
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.